Abstracts tagged "Cell Signaling"

Abstract Number: 2870 • 2017 ACR/ARHP Annual Meeting
Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations
Iain B. McInnes¹, Richard Higgs², Jonathan Lee², William L. Macias², Songqing Na², Robert A. Ortmann², Guilherme Rocha², Thomas Wehrman³, Xin Zhang², Steven H. Zuckerman² and Peter C. Taylor⁴, ¹University of Glasgow, Glasgow, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Primity Bio, Fremont, CA, ⁴NDORMS, University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase (JAK) 1/2 inhibitor, has been approved in the EU for the treatment of adults with moderately to…
Abstract Number: 2862 • 2016 ACR/ARHP Annual Meeting
Whole Blood Phenotyping and Innate and Adaptive Stimulation Reveal Unique Differences in Granulocytes and Innate Pathways of African American SLE Patients with Variable Disease Activity
Samantha Slight-Webb¹, Krista M. Bean¹, Joseph Kheir¹, Bolanle Adebayo¹, Holden T. Maecker², Paul J. Utz³, Judith A. James⁴ and Joel M. Guthridge⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by periods of heightened disease activity. Disease flares significantly affect quality of life and…
Abstract Number: 2931 • 2016 ACR/ARHP Annual Meeting
Endogenous Nur77 Is a Specific Indicator of Antigen Receptor Signaling in Human T and B Cells
Judith Ashouri and Arthur Weiss, Department of Medicine, Division of Rheumatology, 1Howard Hughes Medical Institute, Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
D Intracellular Nur77 protein amounts were assessed by immunofluorescence and flow cytometry in T and B cells isolated from human PBMCs stimulated through their Ag…
Abstract Number: 921 • 2016 ACR/ARHP Annual Meeting
The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ
Robert Hennze¹, Thomas Schlitt¹, Thomas Peters¹, Irina Koroleva², Rebecca Torene², Xiaoyu Jiang³, Marija Curcic Djuric¹, Anis Mir¹, Frank Kolbinger¹ and Christine Huppertz¹, ¹Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, ³Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambdrige, MA
Background/Purpose: In order to better understand the IL-17A signaling pathway we have analyzed the effects of IL-17A in human primary synovial fibroblasts (SF), a…
Abstract Number: 1746 • 2016 ACR/ARHP Annual Meeting
Immune Complex-Induced IL-6 Production By Lupus Prone Mesangial Cells Is Mediated By Neuraminidase Activity
Tamara K. Nowling¹, Kamala Sundararaj² and Leah Siskind³, ¹Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Pharmacology and Toxicology, University of Louisville, Louisville, KY
Background/Purpose: We made the novel observation that glycosphingolipid (GSL) levels and neuraminidase (NEU) (an enzyme that mediates GSL catabolism) activity/expression are altered in the kidneys…
Abstract Number: 1823 • 2016 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in CD4+ T Cell and Monocyte Pathways
Samantha Slight-Webb¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with both genetic and environmental contributions to disease etiology. Patients with different ancestral backgrounds have different…
Abstract Number: 1824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: The management of systemic lupus erythematosus (SLE) is complicated by a heterogeneous clinical presentation. Currently, mycophenolate mofetil (MMF) is a commonly used medication to…
Abstract Number: 797 • 2015 ACR/ARHP Annual Meeting
Divergent Phenotypic Patterns Between Systemic Lupus Erythematosus and Healthy Anti-Nuclear Antibody Positive Individuals Reveal Distinct Differences in B Cell and Myeloid Populations Among Ethnicities
Samantha Slight-Webb¹, Rufei Lu², Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge¹ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder that arises from genetic and environmental factors. Thus, patients with different ancestral backgrounds display differences in…
Abstract Number: 2803 • 2014 ACR/ARHP Annual Meeting
Methotrexate Impacts the Effects of Tofacitinib, but Not Tocilizumab, on Clinically Relevant Biomarkers in Human Primary Cell–Based BioMAP^® Disease Models: Can We Utilize in Vitro Models to Predict Clinical Outcomes?
Alison O'Mahony¹, Ellen L. Berg¹, Xitong Li¹, Markus R. John², Kandeepan Ganeshalingam² and Ernest H. Choy³, ¹BioSeek, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Cardiff University, Cardiff, United Kingdom
Background/Purpose: A number of trials have shown that adding MTX benefits some, but not all, biologics and small molecules to treat RA. Specifically, though treatment…
Abstract Number: 2737 • 2014 ACR/ARHP Annual Meeting
Microrna-155 Suppresses IL-21 Signaling and Production in Systemic Lupus Erythematosus
Tue K. Rasmussen¹, Thomas Andersen¹, Rasmus Bak¹, Gloria Yiu², Kristian Steengaard-Petersen³, Jacob G. Mikkelsen¹, Paul J. Utz⁴, Christian Holm¹ and Bent Deleuran^3,5, ¹Department of Biomedicine, Aarhus University, Aarhus C, Denmark, ²Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Department of Biomedicine, Aarhus University, Aarhus, Denmark
Background/Purpose IL-21 is a key regulator of B cells functions and autoantibody production and is mainly produced by follicular T helper cells. The purpose of…
Abstract Number: 2353 • 2014 ACR/ARHP Annual Meeting
The Nitric Oxide Receptor Soluble Guanylyl Cyclase Is Found in Lymphatic Vessels of Arthritic Mice and Inhibition Alters Lymphatic Pulse
Homaira Rahimi¹, Yawen Ju², Echoe M. Bouta³, Ronald Wood⁴, Christopher T. Ritchlin⁵ and Edward M. Schwarz⁶, ¹Rheumatology, University of Rochester/Golisano Children's Hospit, Rochester, NY, ²Univ of Rochester Med Ctr, University of Rochester, Rochester, NY, ³University of Rochester School of Medicine and Dentistry, Rochester, NY, ⁴Department of Urology, University of Rochester Medical Center, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic erosive inflammatory condition that is characterized by episodes of “flare” due to synovitis of an affected joint. It…
Abstract Number: 1729 • 2014 ACR/ARHP Annual Meeting
Adenosine A2A Receptor (A2AR) Promotes Collagen Type 3 Expression Via β-Catenin Activation
Miguel Perez-Aso¹ and Bruce N. Cronstein², ¹545 1st Ave., New York University, New York City, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose A2AR stimulation promotes collagen 1 and 3 (Col1 and Col3) synthesis, principal mediators of fibrosis and scarring. We have recently demonstrated that the A2AR…
Abstract Number: 1034 • 2014 ACR/ARHP Annual Meeting
Therapeutic Potential of Targeting Sialic Acid Modified Receptors in Osteoarthritis
Maria Dolores Mayan^1,2, Paula Carpintero-Fernández¹, Raquel Gago-Fuentes¹, Marta Varela-Eirin¹, Gary S. Goldberg³ and Francisco Javier Blanco^1,4,5, ¹Cartilage Biology Research Group, Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Email: [email protected], A Coruña, Spain, ³Rowan University, Department of Molecular Biology, School of Osteopathic Medicine, Stratford, NJ, ⁴Rheumatology Division, CIBER-BBN/ISCIII, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁵Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Glycosylated proteins are essential components of the extracellular matrix (ECM) of cartilage and contribute to the maintenance of its function. A shift from a-2,6-…
Abstract Number: 1017 • 2014 ACR/ARHP Annual Meeting
BMP9-Induced pSmad1/5/8 Signaling and Chondrocyte Hypertrophy Are Effectively Inhibited By TGFβ1
Arjan van Caam, Esmeralda Blaney Davidson, Ellen W. van Geffen, Wim B. van den Berg and Peter M. van der Kraan, Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose Osteoarthritis is characterized by degradation of articular cartilage. TGFβ-superfamily signaling via Smad phosphorylation (pSmad) plays a crucial role in cartilage maintenance. Two distinct pSmad…
Abstract Number: 1003 • 2014 ACR/ARHP Annual Meeting
Proteomic Analysis of Connexin 43 Reveals Novel Interactors Related to Osteoarthritis
Raquel Gago-Fuentes¹, Patricia Fernández-Puente^2,3, Paula Carpintero-Fernández¹, Jesus Mateos^2,3, Maria Dolores Mayan¹ and Francisco Javier Blanco^2,3, ¹Cartilage Biology Research Group, Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ³Rheumatology Division, CIBER-BBN/ISCIII, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: We have previously reported that articular chondrocytes in tissue contain long cytoplasmic arms that physically connect two distant cells. Cell-to-cell communication occurs through connexin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].